DX
DXCM.US DexCom Inc
- Market cap
- USD 31.1B
- P/E
- 32.8x
- P/B
- 11.97x
- ROE
- 38.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is DXCM.US undervalued?
Graham numberThe Graham number of DexCom Inc cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
DexCom Inc fundamental analysis
No fundamental analysis for DexCom Inc yet.
DexCom Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About DexCom Inc
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed …
Full company profileDexCom Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
DexCom Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 573M | 719M | 1.03B | 1.48B | 1.93B | 2.45B | 2.91B | 3.62B | 4.03B | 4.66B | 5.13B |
| Gross Profit | 378M | 492M | 664M | 932M | 1.28B | 1.68B | 1.88B | 2.29B | 2.44B | 2.80B | 3.26B |
| Operating Income | -63.9M | -42.5M | -186M | 142M | 300M | 266M | 391M | 598M | 600M | 912M | 1.20B |
| EBITDA | -49.2M | -19.7M | -74.7M | 213M | 377M | 378M | 565M | 917M | 946M | 1.36B | 1.52B |
| Net Income | -65.6M | -50.2M | -127M | 101M | 494M | 217M | 341M | 542M | 576M | 836M | 965M |
| EPS | -0.20 | -0.15 | -0.36 | 0.27 | 1.27 | 0.51 | 0.80 | 1.27 | 1.40 | 2.06 | 2.52 |
| Balance Sheet | |||||||||||
| Total Assets | 403M | 904M | 1.92B | 2.40B | 4.29B | 4.93B | 5.39B | 6.26B | 6.48B | 6.34B | 6.24B |
| Total Liabilities | 119M | 485M | 1.25B | 1.51B | 2.46B | 2.89B | 3.26B | 4.20B | 4.38B | 3.59B | 3.70B |
| Shareholders' Equity | 284M | 419M | 663M | 883M | 1.83B | 2.04B | 2.13B | 2.07B | 2.10B | 2.75B | 2.54B |
| Cash & Short-term Investments | 124M | 549M | 1.39B | 1.53B | 2.71B | 2.73B | 2.46B | 2.72B | 2.58B | 2.00B | 1.82B |
| Total Debt | 45.1M | 361M | 1.02B | 1.16B | 1.84B | 2.16B | 2.15B | 2.59B | 2.59B | 1.39B | 1.39B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 56.2M | 92.0M | 123M | 315M | 476M | 443M | 670M | 749M | 990M | 1.44B | 1.49B |
| Capital Expenditure | 55.7M | 66.0M | 67.1M | 180M | 199M | 389M | 365M | 237M | 359M | 364M | 286M |
| Free Cash Flow | 500K | 26.0M | 56.1M | 135M | 277M | 53.3M | 305M | 512M | 631M | 1.08B | 1.21B |
| Ratios | |||||||||||
| ROE | -23.1% | -12.0% | -19.2% | 11.5% | 27.0% | 10.6% | 16.0% | 26.2% | 27.4% | 30.5% | 38.1% |
| ROA | -16.3% | -5.6% | -6.6% | 4.2% | 11.5% | 4.4% | 6.3% | 8.6% | 8.9% | 13.2% | 15.5% |
| Net Profit Margin | -11.4% | -7.0% | -12.3% | 6.8% | 25.6% | 8.9% | 11.7% | 14.9% | 14.3% | 17.9% | 18.8% |
| Debt to Equity | 0.16x | 0.86x | 1.54x | 1.31x | 1.01x | 1.06x | 1.01x | 1.25x | 1.23x | 0.51x | 0.55x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
DexCom Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | USD 1.23B | 2.89 | 227.3% |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 4:1 on Jun 13, 2022.
Who owns DexCom Inc
- Insiders 0.26%
- Institutions 99.74%
- Public & others 0.00%
- Shares outstanding 373M
- Free float 372M
Top funds holding DXCM.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 12.0M | 3.21% | -2.31% | Sep 2026 |
| Vanguard 500 Index Investor | 9.91M | 2.66% | -3.37% | Sep 2026 |
| Vanguard MStar Mid Cap Index Instl | 8.08M | 2.17% | -3.19% | Sep 2026 |
| Invesco QQQ Trust | 7.85M | 2.10% | -0.10% | Oct 2026 |
| Vanguard MStar Growth Index Investor | 5.05M | 1.35% | +2.91% | Sep 2026 |
| iShares Core S&P 500 ETF | 5.03M | 1.35% | +0.17% | Oct 2026 |
| Fidelity 500 Index | 4.90M | 1.32% | -2.09% | Sep 2026 |
| State Street® SPDR® S&P 500® ETF | 4.58M | 1.23% | -0.25% | Oct 2026 |
| AllianceBernstein US L/C Growth Eqty MF | 3.41M | 0.91% | 0.00% | Jun 2026 |
| Vanguard Health Care Inv | 3.15M | 0.84% | -45.84% | Sep 2026 |
| Vanguard MStar Mid Cap Growth ETF | 2.96M | 0.79% | -0.06% | Sep 2026 |
| State Street®HlthCrSelSectSPDR®ETF | 2.76M | 0.74% | +0.88% | Oct 2026 |
| Invesco S&P 500® Equal Weight ETF | 2.35M | 0.63% | +0.17% | Oct 2026 |
| MFS Mid Cap Growth A | 2.20M | 0.59% | 0.00% | Sep 2026 |
| iShares Russell Mid-Cap Growth ETF | 2.11M | 0.57% | -0.07% | Oct 2026 |
| Vanguard Institutional Index I | 2.00M | 0.54% | -3.24% | Sep 2026 |
| iShares US Medical Devices ETF | 1.80M | 0.48% | -1.12% | Oct 2026 |
| Invesco NASDAQ 100 ETF | 1.79M | 0.48% | +0.15% | Oct 2026 |
| iShares Russell Mid-Cap ETF | 1.59M | 0.43% | -0.06% | Oct 2026 |
| Fidelity Mid Cap Index | 1.45M | 0.39% | -0.79% | Sep 2026 |
Top institutions holding DXCM.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 38.2M | 10.25% | -1.85% | Jun 2026 |
| Vanguard Capital Management, LLC | 25.2M | 6.76% | +0.75% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 19.7M | 5.27% | +2.27% | Jun 2026 |
| State Street Corp | 18.4M | 4.93% | +2.49% | Jun 2026 |
| Amvescap Plc. | 15.3M | 4.10% | +11.82% | Jun 2026 |
| Baillie Gifford & Co Limited. | 14.8M | 3.97% | -5.12% | Jun 2026 |
| Geode Capital Management, LLC | 12.4M | 3.33% | +0.65% | Jun 2026 |
| AllianceBernstein L.P. | 11.7M | 3.14% | -9.52% | Jun 2026 |
| UBS Asset Mgmt Americas Inc | 11.3M | 3.02% | +15.55% | Jun 2026 |
| Wellington Management Company LLP | 8.53M | 2.29% | -8.56% | Jun 2026 |
| Arrowstreet Capital Limited Partnership | 6.87M | 1.84% | +170.06% | Jun 2026 |
| NORGES BANK | 6.87M | 1.84% | -5.69% | Jun 2026 |
| UBS Group AG | 6.07M | 1.63% | +39.44% | Jun 2026 |
| Amundi | 5.60M | 1.50% | -11.51% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 5.16M | 1.38% | +2.27% | Jun 2026 |
| Ameriprise Financial Inc | 4.82M | 1.29% | +13.68% | Jun 2026 |
| Castle Hook Partners LP | 3.87M | 1.04% | +382.68% | Jun 2026 |
| The Goldman Sachs Group Inc | 3.76M | 1.01% | +23.49% | Jun 2026 |
| Franklin Templeton Inc | 3.60M | 0.96% | +37.91% | Jun 2026 |
| Massachusetts Financial Services Company | 3.56M | 0.95% | +84.06% | Jun 2026 |
DexCom Inc company profile
- Company name
- DexCom Inc
- Ticker
- DXCM.US
- Exchange
- USA Stocks
- Listed since
- Apr 14, 2005
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 11,000
- Fiscal year end
- December
- Address
- 6340 Sequence Drive, San Diego, CA, United States, 92121
- Phone
- 858 200 0200
- Website
- dexcom.com
About DexCom Inc
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
DexCom Inc management
10- Mr. Kevin Ronald SayerExecutive Chairman of the Board · born 1958
- Mr. Jacob Steven LeachPresident, CEO & Director · born 1978
- Mr. Jereme M. Sylvain CPAExecutive VP, CFO, COO & Chief Accounting Officer · born 1980
- Mr. Michael Jon Brown J.D.Executive VP, Chief Legal & Compliance Officer · born 1970
- Ms. Sadie M. SternExecutive VP, Chief People & Culture Officer · born 1975
- Mr. Jon ColemanExecutive VP & Chief Commercial Officer · born 1964
- Mr. Peter SimpsonExecutive VP & CTO
- Mr. Sean ChristensenVice President of Finance and Investor Relations
- Mr. Matthew DolanExecutive Vice President of Strategy & Corporate Development · born 1981
- Keri LeoneSenior Director of Global Medical Science & Education